Corpus Intelligence IC Memo — PLAINVIEW HOSPITAL 2026-04-26 17:53 UTC
IC Memo — PLAINVIEW HOSPITAL
Investment Committee Memorandum | NY | 156 beds | Grade C | EBITDA uplift $15.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PLAINVIEW HOSPITAL

CCN 330331 | NASSAU, NY | 156 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

PLAINVIEW HOSPITAL is a 156-bed under-performing / distressed in NASSAU, NY with $213.5M in net patient revenue and a -28.7% operating margin. The hospital serves a payer mix of 49.5% Medicare, 1.9% Medicaid, and 48.6% commercial.

Thesis: Undervalued. Our ML models identify $15.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -28.7% to -21.3% (+736bps).

Net Revenue HCRIS$213.5M
Current EBITDA COMPUTED$-61.2M
Operating Margin COMPUTED-28.7%
Occupancy HCRIS70.3%
Revenue / Bed COMPUTED$1.4M
Net-to-Gross HCRIS26.4%
Distress Probability ML43.4%

2. Market Context & Competitive Position

196
NY Hospitals
-17.5%
State Median Margin
98
Comparable Hospitals

NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -28.7% places it below the state median. Among 98 size-comparable peers (78-312 beds), the median margin is -16.6%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (78-312), prioritizing same-state peers. 98 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PLAINVIEW HOSPITAL (Target)NY156$213.5M-28.7%
HOSPITAL FOR SPECIAL SURGERYNY200$1.12B-29.3%
WHITE PLAINS HOSPITALNY292$884.7M8.7%
ROSWELL PARK CANCER INSTITUTENY142$772.3M-40.1%
SOUTH SHORE UNIVERSITY HOSPITANY312$700.5M-38.5%
LINCOLN MEDICAL&MENTAL HEALTH NY287$693.5M-22.9%
QUEENS HOSPITAL CENTERNY200$637.2M4.9%
JAMAICA HOSPITAL MEDICAL CENTENY280$610.4M-18.6%
SOUTH NASSAU COMMUNITIES HOSPINY312$594.1M-19.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $15.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$4.5M+210bp18mo
Cost to Collect4.5%2.5%$4.3M+200bp12mo
Denial Rate Reduction12.0%6.5%$4.2M+198bp12mo
A/R Days Reduction5200.0%3800.0%$2.6M+122bp9mo
Clean Claim Rate88.0%96.0%$137K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$4.5M
Cost to Collect
$4.3M
Denial Rate Reduction
$4.2M
A/R Days Reduction
$2.6M
Clean Claim Rate
$137K
Total EBITDA Uplift$15.7M
Current EBITDA$-61.2M
+ RCM Uplift+$15.7M
Pro Forma EBITDA$-45.5M
Current Margin-28.7%
Pro Forma Margin-21.3%
WC Released (1x)$8.2M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-94.2M$-246.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-94.2M$-302.0M0.00x-100.0%
Bull Case9.0x11.0x$-84.8M$-280.8M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-84.8M$-331.3M0.00x-100.0%
Bear Case11.0x10.0x$-103.6M$-294.7M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-103.6M$-357.8M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 98 hospitals with 78-312 beds
  • Same-state prioritization (n=99)
  • Comp margins: P25=-26.7% / P50=-16.6% / P75=-9.2%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.